RESEARCHER PROFILE

Susan G. Groshen

← Back to University of Southern California

University of Southern California

Bladder and Urothelial Cancer TreatmentsNeuroblastoma Research and TreatmentsProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentGlioma Diagnosis and Treatment

Susan G. Groshen works in Bladder and Urothelial Cancer Treatments, Neuroblastoma Research and Treatments, Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Glioma Diagnosis and Treatment. Recorded institutional associations include University of Southern California, USC Norris Comprehensive Cancer Center.

775Publications

43,019Citations

106H-index

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

← Return to the university profile

Susan G. Groshen

University of Southern California

Selected research works

Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients

A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan

Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer

The Influence of Margin Width on Local Control of Ductal Carcinoma in Situ of the Breast

Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2

ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy

Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

The Role of Adjuvant Chemotherapy Following Cystectomy for Invasive Bladder Cancer: A Prospective Comparative Trial

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.

FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab

Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.

p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.

Portable Filter-Based Microdevice for Detection and Characterization of Circulating Tumor Cells

Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma

Angiogenesis in Bladder Cancer: Relationship Between Microvessel Density and Tumor Prognosis

Risk Factors for Patients With Pelvic Lymph Node Metastases Following Radical Cystectomy With En Bloc Pelvic Lymphadenectomy: The Concept of Lymph Node Density

A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma.

Critical Role of the Stress Chaperone GRP78/BiP in Tumor Proliferation, Survival, and Tumor Angiogenesis in Transgene-Induced Mammary Tumor Development

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years.